Skip to main content

Medical Treatments

Volume 460: debated on Thursday 17 May 2007

To ask the Secretary of State for Health (1) what estimate she has made of the maximum cost of a quality-adjusted life year available through the NHS; (137734)

(2) what estimate she has made of the cost per quality-adjusted life year of treating patients at high risk of coronary heart disease; and if she will make a statement.

The National Institute for Health and Clinical Excellence (NICE) publishes information on the role of the cost per quality-adjusted life year (QALY) assessments in its “Guide to the Methods of Technology Appraisal”, and indicates in each individual appraisal the range of cost per QALY estimates on which the guidance draws. The guide was published in April 2004 and is available on NICE’s website at:

www.nice.org.uk/page.aspx?o=201973

I have made no assessment of the cost per QALY of treating patients at high risk of coronary heart disease. NICE published a health technology appraisal on statins in January 2006. This guidance relates to the initiation of statin therapy in adults with clinical evidence of cardiovascular disease (CVD) and in adults considered to be at risk of CVD.